Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue 4, 2008, Pages 309-313

  Alvira, Daniel ^a   Ferrer, Isidre ^b   Gutierrez Cuesta, Javier ^a   Garcia Castro, Beatriz ^a   Pallàs, Merce ^a   Camins, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

cdk5; Cell cycle; E2F 1; Parkinson's disease

Indexed keywords

CALPAIN; CYCLIN DEPENDENT KINASE 5; PROTEIN P25; PROTEIN P35; TRANSCRIPTION FACTOR E2F1;

ADULT; AGED; ARTICLE; CELL CYCLE; CINGULATE GYRUS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; CALPAIN; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE 5; FEMALE; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 44249113558     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.09.005     Document Type: Article

References (26)

1. Rao S.S., Hofmann L.A., and Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 74 (2006) 2046-2054
2. Camins A., Verdaguer E., Folch J., Canudas A.M., and Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19 (2006) 453-460
3. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., and Smith M.A. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65 (2006) 631-641
4. Smith P.D., Mount M.P., Shree R., Callaghan S., Slack R.S., Anisman H., et al. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26 (2006) 440-447
5. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97 (2000) 2875-2880
6. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. J Neurochem 76 (2001) 1785-1793
7. Mouatt-Prigent A., Karlsson J.O., Agid Y., and Hirsch E.C. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?. Neuroscience 73 (1996) 979-987
8. Webber K.M., Casadesus G., Zhu X., Obrenovich M.E., Atwood C.S., Perry G., et al. The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Des 12 (2006) 691-697
9. Jordan-Sciutto K.L., Dorsey R., Chalovich E.M., Hammond R.R., and Achim C.L. Expression patterns of retinoblastoma protein in Parkinson disease. J Neuropathol Exp Neurol 62 (2003) 68-74
10. Webber K.M., Raina A.K., Marlatt M.W., Zhu X., Prat M.I., Morelli L., et al. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev 126 (2005) 1019-1025
11. Alvira D., Tajes M., Verdaguer E., Acuna-Castroviejo D., Folch J., Camins A., et al. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 40 (2006) 251-258
12. Smith P.D., Crocker S.J., Jackson-Lewis V., Jordan-Sciutto K.L., Hayley S., Mount M.P., et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 100 (2003) 13650-13656
13. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
14. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., and Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999) 615-622
15. Cruz J., and Tsai L. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10 (2004) 452-458
16. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., and Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40 (2003) 471-483
17. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
18. Lee S.S., Kim Y.M., Junn E., Lee G., Park K.H., Tanaka M., et al. Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol Aging 24 (2003) 687-696
19. Crocker S.J., Smith P.D., Jackson-Lewis V., Lamba W.R., Hayley S.P., Grimm E., et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23 (2003) 4081-4091
20. Nakamura S., Kawamoto Y., Nakano S., Akiguchi I., and Kimura J. p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 94 (1997) 153-157
21. Smith P.D., O'Hare M.J., and Park D.S. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 10 (2004) 445-451
22. Brion J.P., and Couck A.M. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 147 (1995) 1465-1476
23. Hoglinger G.U., Breunig J.J., Depboylu C., Rouaux C., Michel P.P., Alvarez-Fischer D., et al. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A 104 (2007) 3585-3590
24. Waldmeier P., Bozyczko-Coyne D., Williams M., and Vaught J.L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72 (2006) 1197-1206
25. Chergui K., Svenningsson P., and Greengard P. Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S A 101 (2004) 2191-2196
26. Kim S.J., Sung J.Y., Um J.W., Hattori N., Mizuno Y., Tanaka K., et al. Parkin cleaves intracelular alpha-synuclein inclusions via the activation of calpain. J Biol Chem 278 (2003) 41890-41899